Fifth Third Bancorp
NTLA icon

Fifth Third Bancorp’s Intellia Therapeutics NTLA Stock Holding History

Fifth Third Bancorp’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.9K Buy
+2,953
New +$37.6K ﹤0.01% 3295
2024
Q2 		– Sell
-150
Closed -$4.13K – 2494
2024
Q1 		$4.13K Sell
150
-8
-5% -$222 ﹤0.01% 2113
2023
Q4 		$4.82K Buy
158
+8
+5% +$230 ﹤0.01% 2194
2023
Q3 		$4.74K Hold
150
– – ﹤0.01% 2184
2023
Q2 		$6.12K Hold
150
– – ﹤0.01% 2142
2023
Q1 		$5.59K Hold
150
– – ﹤0.01% 2299
2022
Q4 		$5.23K Hold
150
– – ﹤0.01% 2190
2022
Q3 		$8K Hold
150
– – ﹤0.01% 2029
2022
Q2 		$8K Hold
150
– – ﹤0.01% 2081
2022
Q1 		$11K Sell
150
-150
-50% -$12.7K ﹤0.01% 2028
2021
Q4 		$35K Buy
300
+279
+1,329% +$35K ﹤0.01% 1665
2021
Q3 		$3K Sell
21
-16
-43% -$2.42K ﹤0.01% 2363
2021
Q2 		$6K Buy
+37
New +$2.88K ﹤0.01% 2169
2019
Q1 		– Sell
-2
Closed – – 2254
2018
Q4 		$0 Buy
+2
New +$37 ﹤0.01% 2312
2018
Q3 		– Sell
-165
Closed -$5K – 2273
2018
Q2 		$5K Buy
+165
New +$4K ﹤0.01% 2050

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fifth Third Bancorp's NTLA Position: Q1 2026 in Review

Fifth Third Bancorp opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 2,953 shares worth $37.9K. The stake represents ﹤0.01% of the portfolio and ranks #3295 among its holdings. This is a return to the name: Fifth Third Bancorp previously reported a position in NTLA as recently as Q1 2024.

Fifth Third Bancorp first reported a position in NTLA in Q2 2018 and has held it in 15 quarters since. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Fifth Third Bancorp held 2,953 shares of Intellia Therapeutics worth $37.9K as of Q1 2026.
  • Intellia Therapeutics was a new Fifth Third Bancorp position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q1 2026, its #3295 holding.
  • Fifth Third Bancorp first reported a position in Intellia Therapeutics in Q2 2018 and has held it in 15 quarters since.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Fifth Third Bancorp's 13F filing for Q1 2026, filed 1 May 2026.